Multiple Myeloma — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for multiple myeloma. 73 active patents protecting 5 drugs from 5+ originators. First major cliff: 2026. Daily refresh.

5
Approved drugs
73
Active US patents
54/100
Avg vulnerability
$8.1B
Annual revenue covered

Originators in Multiple Myeloma

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Amgen 24 patents Baxter 15 patents Generic (originally Merck) 15 patents Bristol-Myers Squibb 12 patents Shilpa 7 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating multiple myeloma. Each bar = one year. Y-axis scaled to peak year (14 patents).

3
26
14
27
10
28
3
29
5
30
2
32
6
33
3
34
9
35
7
36
3
37
1
39
1
41

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Kyprolis
carfilzomib
 Amgen 24 60 $1.3B 2026-07-20
Cytoxan (Lyophilized)
cyclophosphamide
 Baxter 15 49 $1.0B 2035-06-26
Decadron
dexamethasone
 Generic (originally Merck) 15 46 — 2027-12-19
Revlimid
lenalidomide
 Bristol-Myers Squibb 12 54 $5.8B 2027-04-27
Velcade
bortezomib
 Shilpa 7 62 — 2032-11-03

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
7417042 Kyprolis other 80 2027-01-20
7417042 Kyprolis other 80 2027-01-20
7417042 Kyprolis other 80 2027-01-20
8741929 Revlimid method of use 80 2028-03-08
8741929 Revlimid method of use 80 2028-03-08
8741929 Revlimid method of use 80 2028-03-08
8741929 Revlimid method of use 80 2028-03-08
8741929 Revlimid method of use 80 2028-03-08
8741929 Revlimid method of use 80 2028-03-08
RE47954 Kyprolis method of use 76 2029-10-21

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
7417042 Kyprolis composition of matter 22 2026-07-20
7417042 Kyprolis composition of matter 22 2026-07-20
10537585 Decadron formulation 25 2037-12-18
10159683 Decadron formulation 25 2034-05-23
7465800 Revlimid composition of matter 27 2027-04-27
7465800 Revlimid composition of matter 27 2027-04-27
7465800 Revlimid composition of matter 27 2027-04-27
7465800 Revlimid composition of matter 27 2027-04-27
7465800 Revlimid composition of matter 27 2027-04-27
7465800 Revlimid composition of matter 27 2027-04-27

Related